

**GEORGIA BOARD OF PHARMACY**  
**Conference Call**  
**2 Peachtree Street, NW, 6<sup>th</sup> Floor**  
**Atlanta, GA 30303**  
**November 18, 2020**  
**9:00 a.m.**

**The following Board members were present:**

Mike Faulk, Vice-President  
Carrie Ashbee  
Michael Azzolin  
Michael Brinson  
Cecil Cordle  
Chuck Page  
Bill Prather  
Dean Stone

**Staff present:**

Eric Lacefield, Executive Director  
Dennis Troughton, Director, GDNA  
Michael Karnbach, Deputy Director, GDNA  
Max Changus, Assistant Attorney General  
Kimberly Emm, Attorney  
Brandi Howell, Business Support Analyst I

**Visitors:**

Bethany Sherrer, Medical Association of Georgia  
Alissa Smith, Amber Pharmacy  
Stephen Snow, Bendin Sumrall & Ladner, LLC  
Becca Hallum, Georgia Hospital Association  
Lea Winkles, Mercer University  
Dr. Todd Davidson, Amber Pharmacy  
Joe Acierno, Amber Pharmacy  
Teresa Kelly, Amber Pharmacy

**Open Session**

Vice-President Faulk established that a quorum was present and called the meeting to order at 9:13 a.m.

Mr. Lacefield asked the visitors on the call to send an email via the “Contact Us” portal on the website if he/she would like his/her name reflected as being in attendance in the minutes.

Vice-President Faulk welcomed new board members, Mr. Cecil Cordle and Mr. Chuck Page. Vice-President Faulk recognized Ms. Lisa Harris in appreciation for the job she did as Board President.

**Approval of Minutes**

Mr. Brinson made a motion to approve the October 14, 2020 Public and Executive Session Conference Call minutes. Mr. Azzolin seconded and the Board voted unanimously in favor of the motion.

**Report of Licenses Issued**

Mr. Stone made a motion to ratify the list of licenses issued. Mr. Brinson seconded and the Board voted unanimously in favor of the motion.

**Petitions for Rule Waiver or Variance**

Mr. Changus explained the rule petition process to Mr. Cordle and Mr. Page. He stated that the statute allows individuals to request relief under the rules. Mr. Changus explained that individuals may ask for a waiver or variance from those rules. He stated that the individual must identify the rule and explain what his/her substantial hardship is.

The Board discussed the rule variance petition from Amber Specialty Company, PHNR000444. Mr. Lacefield informed the Board that there were several representatives from Amber Specialty Company on the call if the Board had any questions. Vice-President Faulk responded by requesting a representative from Amber Specialty Company explain the request. Alissa Smith provided the Board background information on the facility. She stated that Amber Specialty Company is a specialty pharmacy that focuses on long term treatment to ill patients. Ms. Smith explained that its headquarters are in Omaha. She stated that Amber Specialty Pharmacy has a small brick and mortar pharmacy in Georgia. She further stated that Amber Specialty Pharmacy could not provide access for patients without backup and background services from its Omaha location.

Teresa Kelly, RPh, in Omaha spoke to the Board. Ms. Kelly explained that she oversees the Center of Excellence, which are disease-state focused teams that are organized around the patient. She explained that Amber's Patient Access Team handles the referrals received from the doctor's office. She stated that they do a comprehensive review of insurance coverage for the patient, specifically for specialty medications. Ms. Kelly explained that the team will investigate all insurance coverage options to determine the lowest out of pocket cost for the patient. She further explained that the pharmacist for the Center of Excellence does an initial clinical review of the prescriptions before they are filled and determines the appropriateness for the patient. Ms. Kelly stated that she helps to complete initial patient counseling and ongoing plan of care. She stated that there is also a Customer Care Center that assists with outreach to patients and doctors.

Dr. Todd Davidson, Pharmacy Manager, spoke to the Board. Dr. Davidson explained that he has been impressed with the level of service that Amber Specialty Pharmacy provides to its pharmacy patients as well as transplant patients. He stated that providing this level of care to patients takes numerous team members. He explained that not only traditional pharmacy staff interact with these patients, but also staff at the Center of Excellence. Dr. Davidson stated that it is important for the Board to know he is licensed in Georgia and will do the final verification, fill the prescription, dispense the prescription and counsel the patient. He explained that with the Amber Care model, the Omaha office, with this variance can still provide specialized services for the pharmacy in Georgia. Dr. Davidson stated that without the use of these shared services, patients in Georgia could not experience Amber's specialized care team, which provides exceptional and outstanding patient care and helps the patient do that at an affordable cost.

Vice-President Faulk commented that they are explaining all of these services provided, but what they are requesting to do is remote order processing in another state. He asked if they can still provide those services without the variance. Ms. Smith responded that one person cannot serve all of the patient population and do all of the background work. Vice-President Faulk stated that he does not know if the rule prohibits them from doing that. Mr. Azzolin referred to Rule 480-36-.03 which requires the individual who is the secondary pharmacist to be licensed and within in the state of Georgia. He explained that the rule Amber Specialty Pharmacy is requesting to waive requires the remote processing to be done from outside of the state of Georgia. Mr. Azzolin went on to state that O.C.G.A. § 26-4-5(37.2) reads in part, *"Remote order entry" means the entry made by a pharmacist licensed in this state, who is an employee or contractor of a pharmacy licensed in this state or that holds a nonresident pharmacy permit issued pursuant to Code Section 26-4-114.1, from a remote location anywhere in the United States...* He continued by stating that O.C.G.A. § 26-4-27 reads, *"The board may establish such rules and regulations not inconsistent with this chapter and as in its judgment will best carry out the requirements thereof."* Mr. Azzolin stated that his point is this requirement is required by rule, not law, and based on what is consistent with the law is it can be anywhere in the United States. Mr. Azzolin proposed that the Board grant the waiver, but also change the rule because it is not consistent with the law. Mr. Prather responded by stating that the Board has previously not allowed this because if a problem arises in the future, the Board has no purview over a pharmacy or pharmacist in another state. He asked what Mr. Changus' thoughts were on the matter. Mr. Changus commented by stating that he thinks the idea of remote order entry is an

expansion of what we think of traditional pharmacy where the order is brought in, filled and dispensed at the same location. He continued by stating that the idea over time was to maintain control over it by insuring all of it would be done in the state to have greater oversight. Mr. Azzolin stated that relative to oversight, if these locations hold a Georgia license, the Board would be able to revoke the license if something were to happen. He further stated that the Board would still have purview over that license whether they are in the state or across the state line. He added that he would want patients to have access to that pharmacy. Mr. Prather asked Mr. Azzolin if he was saying there are no pharmacists in the state of Georgia that are capable of doing what Amber Specialty Pharmacy does. Mr. Azzolin responded by stating that is not what he was stating. Mr. Azzolin stated that regardless of where they come from, he does not feel the Board should hinder access to patient care if it has control of the license. Ms. Emm stated that remote order entry is viewed differently than remote order processing, and that remote order entry is limited to hospitals only. Mr. Azzolin responded that he understood. He stated that his point is that O.C.G.A. § 26-4-27 reads, *“The board may establish such rules and regulations not inconsistent with this chapter and as in its judgment will best carry out the requirements thereof”*, and that is relative to things like remote order processing. Mr. Azzolin stated that he understands it is a different license type, but thinks it would be more consistent if it were from anywhere in the United States.

Director Troughton commented that if GDNA inspected that retail pharmacy and they were doing the data entry, dispensing and final order verification and they were just using the non-resident pharmacy for support functions, GDNA would not have an issue with that and does not see the need for a waiver. Mr. Stone and Mr. Brinson agreed. Mr. Azzolin asked if at any point is Amber Specialty Pharmacy processing the prescription from Omaha, or are they just providing clinical support? Dr. Davidson responded by stating that the initial processing is done in Omaha and Atlanta does not see the prescription until it is ready to be filled. Mr. Azzolin responded by stating that this scenario fits the “primary vs. secondary pharmacy”. He stated they are doing retail remote data processing and that is why this rule needs to be waived. Director Troughton commented that it sounds like Omaha is the primary pharmacy and Atlanta does not see it until the prescription is ready to be filled. He asked if the prescription is transferred to Atlanta. Ms. Kelly responded that they all share “real time access” to the same prescription information through the same computer system. She continued by stating that the certified technician and pharmacist in Omaha are operating under the non-resident pharmacy license. Ms. Kelly explained that the prescription is not transferred as it just goes into the queue when it is ready to be dispensed and that is when Dr. Davidson in Atlanta would see it. Mr. Azzolin stated that everything is done electronically. He stated that Rule 480-36-.03 requires a primary dispensing pharmacy and secondary remote entry pharmacist. He further stated the data is virtual on their server. Mr. Azzolin continued by stating that the secondary remote entry pharmacist is processing that pursuant to these rules; however, the problem for them is that person is outside the state. Mr. Azzolin discussed subsections of the rule that needed to be eliminated so that this is not an issue for anyone else in the future.

Mr. Changus stated that the question he has is concerning the reasoning for the variance. He stated that for this particular business model, much of the data entry is done in Omaha. He asked what is the substantial hardship or unique situation in this case that would determine that a waiver or variance is required. Mr. Azzolin commented that, while he is not speaking on their behalf, he thinks it would be a financial hardship based on the written documentation provided with their rule petition. He continued by stating that the Board has granted variances for financial hardship since he has been on the Board. Ms. Smith affirmed that was correct. She stated that without the variance there would be a duplication of services which would be an unreasonable expense and would create a significant burden, along with limiting the ability to expand this model in Georgia. Mr. Prather suggested tabling the petition and commented that the Board’s rules are in place for a reason and that reason is to protect the citizens of Georgia. Mr. Azzolin responded by stating that he would hate for there to be a delay in patient care just for this one rule variance. He suggested the Board consider discussing the rule itself at another meeting, but make a determination today on the rule petition. Mr. Brinson agreed with Mr. Azzolin. Mr. Prather made a motion to table the petition to allow

additional time for the Board to consider. There was no second. Mr. Azzolin made a motion to grant the rule variance petition. Mr. Brinson seconded and the Board voted in favor of the motion, with the exception of Mr. Prather, who opposed.

The Board discussed the rule waiver petition from MBA Wellness Centers, LLC, PHOP000058: Mr. Brinson made a motion to grant the rule waiver petition. Discussion was held. Mr. Page asked what the specific waiver was for as he did not have access to the materials. Vice-President Faulk explained that the pharmacy was requesting a waiver of Rule 480-18-.05(1), which requires floor space to be at a minimum of 150 square feet. Mr. Prather suggested amending the language in the rule. With no further discussion, Mr. Stone seconded and the Board voted unanimously in favor of the motion.

### **Correspondence from Walter Williams**

The Board considered this correspondence requesting clarification regarding batch compounding and first dose admixtures. The Board directed staff to respond by stating if there is similar ownership between the entities and the medications are patient-specific prescriptions, that would be permissible. In regards to his questions about batch compounding, the Board suggested he contact the FDA regarding 503b requirements.

### **Correspondence from Bridget O'Brien**

The Board considered this correspondence requesting clarification as to whether or not the RECELL Device requires a wholesale license. Ms. Emm explained that the Board previously considered this matter in 2019 and that Ms. O'Brien is requesting the Board to reconsider its decision as there seems to have been some confusion regarding the product they provide. Ms. Emm stated that it appears the RECELL Device is something not provided to patients, but rather to facilities, and is not something that would be contained in a pharmacy. Ms. Emm stated it is up to the Board as to whether or not it feels this product is considered a device utilized in the practice of pharmacy. After further discussion, the Board recommended tabling the matter and directing staff to respond by requesting additional information.

### **Correspondence from Stephen Snow**

Mr. Snow was on the conference call and spoke to the Board regarding his request. Mr. Snow explained that his correspondence is a follow up to a previous correspondence submitted in the Spring of 2018. He stated that the correspondence requested the Board strike the requirement in Rule 480-16-.02(03) for written authorization from the patient in order for a pharmacy to deliver the patient's drugs to a medical practitioner. He further stated that at the Board's previous meeting the Board was not inclined to strike the rule altogether, but suggested he provide proposed language for revising the rule. Mr. Snow stated that the reason for the request to revise the rule is because of a number of difficulties that render it impossible or impractical for a patient to get written authorization before the prescription is provided to the patient's doctor. Specifically, he stated that he is talking about first dose administration in emergency settings where the patient is incapable of giving that written consent. Mr. Snow stated that the Composite Medical Board was supportive of the request to strike the provision. He further stated that the Board of Pharmacy suggested he revise the rule to allow for authorization to be either written or verbal, or in situations where it would be impossible for the patient to provide written or verbal authorization, the doctor would make a note on the prescription drug order and document that the patient is not capable of providing the written authorization such as in an emergency or hospice situation. Discussion was held by the Board. Mr. Prather inquired as to what would happen if a patient gave an oral or verbal authorization and there were issues down the road. He asked where would that leave the patient. Mr. Snow responded by stating this would be the patient communicating directly with the pharmacy and the pharmacy would make a notation on the prescription record in the pharmacy.

Ms. Emm commented that she believes there would be an enforcement issue with "verbal" authorization. Director Troughton agreed. He stated that with today's technology, there always needs to be something in

writing. Mr. Azzolin agreed with Director Troughton. After further discussion, the Board stated it was not inclined to revise the rule at the moment and suggested having further discussion on the matter at another time once the appropriate research was done.

### **Correspondence from Scott Brunner, Alliance for Pharmacy Compounding (APC)**

The Board considered this correspondence requesting the Board's feedback regarding the FDA's Compounding Memorandum of Understanding (MOU). Mr. Changus commented that this issue has been brought to the Board's attention previously. He stated that there are two issues, one of which is practicality. Specifically, how will the Board comply with requirements asked for by FDA, especially with the sharing of investigative information. He continued by stating that there would be a new role for the Board, which would probably be handled by GDNA. Mr. Changus stated the second issue is the legal aspect of it. He stated that the Board can enter into contracts, but it is a question of how much can the Board bind itself without the input of the General Assembly, especially to the extent that it is asking for extra duties to be performed. Mr. Changus stated that there is a request for the Board to provide feedback. He stated that the Board has a year to determine whether or not it will sign the MOU.

Director Troughton stated that he appreciates the inquiry. He further stated that this MOU has been in the works for a while and there are a number of items that would need to be discussed with the Board. He added that the MOU would definitely impact GDNA more than the Board as this certainly would increase the burden on GDNA and tap into its resources. Mr. Azzolin requested clarification concerning the portion of the letter that states if Georgia does not sign, a 5% cap will be imposed on a Georgia pharmacy's ability to ship compounded items outside of the state. Director Troughton affirmed that was correct. Mr. Azzolin asked what kind of burden would this put on a regulatory environment and what kind of restrictions would this put on pharmacies in Georgia relative to shipping outside of the state to a pharmacy that does or does not sign the MOU. Director Troughton responded by stating commerce would be inhibited. Mr. Azzolin asked how long does the Board have to make a decision. Director Troughton responded that the Board must make a decision by 10/26/2021. Mr. Azzolin stated that he thinks the Board should do its research before making a decision. After further discussion, the Board directed Director Troughton to review the questionnaire and bring back to the Board for discussion. Mr. Snow commented that one of the concerns the APC has is they do not want states to respond too quickly. He suggested the Board wait until closer to the 365<sup>th</sup> day, if possible, to allow the APC time to review. Vice-President Faulk affirmed the Board will wait to respond.

### **Correspondence from Lisa Smith, Walmart**

The Board viewed this correspondence for informational purposes only.

### **Georgia Drugs and Narcotics Agency – Dennis Troughton**

Director Troughton shared his sentiments on Lisa Harris. He stated that she was a delightful person, very professional and will be missed.

Director Troughton welcomed Mr. Cordle and Mr. Hamby to the Board. He stated that both, along with any other board members, were welcome to visit GDNA to see what they do.

Director Troughton reported that GDNA has conducted 1100 inspections and received 134 complaints for FY2021.

### **Attorney General's Report – Max Changus**

Mr. Changus introduced himself to Mr. Cordle and Mr. Page and explained his role with the Board.

### **Executive Director's Report – Eric Lacefield**

Mr. Lacefield welcomed Mr. Cordle and Mr. Page to the Board.

**Continuing Education Report:** Report presented. Mr. Stone made a motion to ratify the below continuing education programs approved since the previous meeting. Mr. Prather seconded and the Board voted unanimously in favor of the motion.

Date of Program	Hours	Sponsoring Group	Program Title	CE Code
11/12/2020	1	Kaiser Permanente Georgia	ReCAP: Community Acquired Pneumonia Guideline Major Updates Review	2020-0014
12/03/2020	1	Kaiser Permanente	It's a Real Pain : Management of Fibromyalgia Syndrome	2020-0015

**Practical Exam:** Mr. Lacefield reported that the Board approved the calendar for the 2021 year. He stated that the January exam in particular is what he wanted to discuss. He stated that South University has inquired as to whether or not the Board intends to hold that practical exam as South is planning for their spring term. Mr. Lacefield explained that the emergency rule remains in effect for the duration of the emergency and for a period of not more than 120 days thereafter. He stated that the January exam would fall into the 120 day timeframe, as well as March exam. Mr. Lacefield stated that he assumes, in light of the pandemic, the Board’s intent is not to gather publicly. Mr. Prather made a motion for the Board to direct Mr. Lacefield to respond to South University by stating that it would not be conducting a January practical examination due to the pandemic. Ms. Ashbee seconded and the Board voted unanimously in favor of the motion.

**HHS Announcement:** Mr. Lacefield reported that HHS recently announced it is partnering with pharmacies to increase access to the COVID-19 vaccine once a vaccine is authorized or approved. He stated that the Department of Public Health (DPH) has reached out to Ms. Harris and requested the Board to provide a link to participating pharmacies that would be distributing vaccines. Mr. Lacefield stated that DPH has not provided a link yet, but Ms. Harris requested it be posted to the Board’s website once it is available.

**COVID Vaccination Clinics:** Mr. Lacefield reported that he received an email from Mercer University stating that the school would be happy to participate in the vaccine distribution by having its student externs distribute to the population; however, state law has restrictions on what an extern can do. He stated that Mercer University is hoping the Board would support them by reaching out to the Governor’s office and request, that in light of the State of Emergency, the University be allowed to provide vaccinations. Mr. Azzolin commented that he thinks that would be a great idea. He stated that pharmacy schools can utilize students as long as the student has been through some formal training. Mr. Brinson agreed. Mr. Prather agreed with the caveat that whomever administers it has to go through the appropriate training. Mr. Prather made a motion for the Board to direct Mr. Lacefield to forward Mercer University’s email to the Governor’s office for consideration. Mr. Stone seconded and the Board voted unanimously in favor of the motion. Mr. Azzolin inquired if this would only be during the State of Emergency. Mr. Lacefield answered in the affirmative.

**Licensing System:** Mr. Lacefield informed the Board that its licensing system needs to be updated and in order to do so, the system will need to be taken down for a few days. He explained that this will cause a disruption in services for pharmacists that are now renewing. As such, a statement will be posted to the Board’s website stating that the system will be down Friday afternoon until Monday.

**Legal Services – Kimberly Emm**

Ms. Emm welcomed Mr. Cordle and Mr. Page.

Ms. Ashbee made a motion and Mr. Prather seconded, and the Board voted to enter into **Executive Session** in accordance with O.C.G.A. § 43-1-19(h)(2) and § 43-1-2(k) to deliberate and to receive information on applications, investigative reports and the Assistant Attorney General's report. Voting in favor of the motion were those present who included Carrie Ashbee, Michael Azzolin, Michael Brinson, Cecil Cordle, Mike Faulk, Chuck Page, Bill Prather, and Dean Stone.

**Executive Session**

**Appearances**

- C.C.
- J.L.A.
- L.T.W.

**Georgia Drugs and Narcotics Agency – Dennis Troughton**

- A.U.M.C.I.P.
- P.P.
- I.C.I.
- J.D.C.
- K.P.

**Cognizant's Report – Mike Faulk**

- GDNA Case # A33485
- GDNA Case # T33510
- GDNA Case # T33508
- GDNA Case # T33415
- GDNA Case # B33428
- GDNA Case # B33168
- GDNA Case # A33487
- GDNA Case # A32862
- GDNA Case # A33493
- GDNA Case # A33484
- GDNA Case # B33396
- GDNA Case # B33480
- GDNA Case # A33417
- GDNA Case # SB33332
- GDNA Case # T33448
- GDNA Case # B33457
- GDNA Case # B33471
- GDNA Case # B33399
- GDNA Case # B33386
- GDNA Case # B33259
- GDNA Case # A33430
- GDNA Case # B33379
- GDNA Case # A33402
- GDNA Case # B33425
- GDNA Case # T33513

**Attorney General's Report – Max Changus**

Mr. Changus presented the following consent orders for acceptance:

- B.P.
- H.P.
- B.P.
- C.V.S.P.
- P.F.P.I.
- U.S.S.F.
- S.P.C.
- H.E.S.
- K.H.
- E.A.
- J.W.
- G.M.B.

Mr. Changus discussed the following cases:

- P.S.P.
- M.F.W.

Mr. Changus discussed board member recusal from applications/investigative matters.

**Executive Director's Report – Eric Lacefield**

No report.

**Legal Services – Kimberly Emm**

The Board received legal advice regarding O.C.G.A. § 50-18-70.

**Applications**

- C.A.S.
- C.O.L.
- J.A.H.
- L.A.D.
- T.L.M.
- M.H.
- J.C.L.
- A.R.B.
- L.K.T.L.
- T.E.C.
- B.M.V.
- M.J.W.
- A.J.S.
- A.H.
- S.E.T.
- T.C.
- M.P.S.
- B.V.M.
- M.S.S.
- P.T.I.R.
- S.P.



## Correspondences/Requests

- C.C.V.S.S.I.S.
- L.L.C.P.S.I.
- D.I.P.C.A.
- D.P.S.
- D.P.S.
- S.
- I.P.C.
- I.P.C.
- B.
- T.P.U.I.
- P.S.
- H.P.
- P.S.P.
- C.C.S.M.
- C.C.S.M.
- C.C.S.M.
- C.C.S.M.
- H.B.I.
- P.C.C.
- W.P.N.
- W.P.N.
- P.E.H.
- T.S.Q.
- A.E.B.
- M.C.P.
- J.C.H.
- J.A.S.
- A.J.
- D.W.W.
- E.N.D.
- L.H.J.

No votes were taken in Executive Session. Vice-President Faulk declared the meeting back in Open Session.

## **Open Session**

### Miscellaneous

**Election of Officers:** Mr. Brinson made a motion for Mr. Faulk to serve as President. Mr. Stone seconded and the Board voted unanimously in favor of the motion.

Mr. Prather made a motion for Mr. Brinson to serve as Cognizant and Vice-President. Mr. Stone seconded and the Board voted unanimously in favor of the motion.

Mr. Prather made a motion for the Board to take the following actions:

### Appearances

- C.C. Request to reinstate pharmacist license Denied request

- J.L.A. Request to reinstate pharmacist license Refer to the Department of Law
- L.T.W. Denied Pharmacy Technician Upheld denial

### **Georgia Drugs and Narcotics Agency – Dennis Troughton**

- A.U.M.C.I.P. Correspondence The Board viewed this correspondence for informational purposes only.
- P.P. Correspondence The Board viewed this correspondence for informational purposes only.
- I.C.I. Request regarding software system Approved request
- J.D.C. Request to terminate probation Approved request
- K.P. Update provided

### **Cognizant’s Report – Mike Faulk**

- GDNA Case # A33485 Accept Private Interim Consent Order
- GDNA Case # T33510 Accept Signed Voluntary Surrender
- GDNA Case # T33508 Accept Signed Voluntary Surrender
- GDNA Case # T33415 Revoke Technician Registration
- GDNA Case # B33428 Revoke Technician Registration
- GDNA Case # B33168 Misfill Policy #1 / Refer to the Department of Law
- GDNA Case # A33487 Refer to the Department of Law
- GDNA Case # A32862 Refer to the Department of Law
- GDNA Case # A33493 Refer to the Department of Law
- GDNA Case # A33484 Update license status to “Null and Void”
- GDNA Case # B33396 Investigative Interview
- GDNA Case # B33480 Close with letter of concern
- GDNA Case # A33417 Refer to the Department of Law
- GDNA Case # SB33332 Refer to the Department of Law
- GDNA Case # T33448 Close with no action
- GDNA Case # B33457 Close with no action
- GDNA Case # B33471 Misfill Policy #1
- GDNA Case # B33399 Close with no action
- GDNA Case # B33386 Close with no action
- GDNA Case # B33259 Close with no action
- GDNA Case # A33430 Close with no action
- GDNA Case # B33379 Close with no action
- GDNA Case # A33402 Refer to the Department of Law
- GDNA Case # B33425 Close with no action
- GDNA Case # T33513 Revoke Technician Registration

### **Attorney General’s Report – Max Changus**

Mr. Changus presented the following consent orders for acceptance:

- Brownings Pharmacy Public Consent Order accepted
- Hometown Pharmacy Public Consent Order accepted
- B.P. Private Consent Order accepted
- CVS Pharmacy #7893 Public Consent Order accepted
- Pierre Fabre Pharm. Public Consent Order accepted
- US Specialty Formulations Public Consent Order accepted

- Stricklands Pharmacy Corp Public Consent Order accepted
- H.E.S. Private Consent Order accepted
- K.H. Private Consent Order accepted
- Elleni Abebe Public Consent Order accepted
- Julius Williams III Public Consent Order accepted
- G.M.B. Voluntary Surrender to be accepted and signed with express permission upon receipt of the original

Mr. Changus discussed the following cases:

- P.S.P. Close case with no action
- M.F.W. Close case with no action

Mr. Changus discussed board member recusal from applications/investigative matters.

### **Executive Director’s Report – Eric Lacefield**

No report.

### **Legal Services – Kimberly Emm**

The Board received legal advice regarding O.C.G.A. § 50-18-70.

### **Applications**

- |                                   |                                     |  |
|-----------------------------------|-------------------------------------|--|
| • Charles A. Smalls               | Pharmacy Technician                 | Approved for registration  |
| • Chelsey O. Lee                  | Pharmacy Technician                 | Approved for registration  |
| • Jacob A. Heeter                 | Pharmacy Technician                 | Approved for registration  |
| • L.A.D.                          | Pharmacy Technician                 | Denied registration  |
| • Tierra L. Mitchell              | Pharmacy Technician                 | Approved for registration  |
| • Mercedes Hamilton               | Pharmacy Technician                 | Approved for registration  |
| • Joyce C. Lilly                  | Pharmacy Technician                 | Approved for registration  |
| • Alanna R. Baughn                | Pharmacy Technician                 | Approved for registration  |
| • Loan Kim Thi Le                 | Pharmacy Technician                 | Approved for registration  |
| • T.E.C.                          | Pharmacy Technician                 | Table pending receipt of additional information                          |
| • B.M.V.                          | Pharmacy Technician                 | Denied registration  |
| • M.J.W.                          | Pharmacist Intern                   | Table pending receipt of additional information                          |
| • A.J.S.                          | Pharmacist Reinstatement            | Schedule to meet with the Board once additional information is received. |
| • A.H.                            | Pharmacist Reciprocity              | Approved to sit for the exam   |
| • S.E.T.                          | Pharmacist Reciprocity              | Approved to sit for the exam   |
| • T.C.                            | Pharmacist Reciprocity              | Approved to sit for the exam   |
| • M.P.S.                          | Pharmacist Renewal                  | Approved for renewal   |
| • B.V.M.                          | Pharmacist Certification of DTM     | Tabled pending receipt of additional information                         |
| • Medicus Surgical Solutions, LLC | Durable Medical Equipment Suppliers | Approved application   |
| • P.T.I.R.                        | Manufacturing Pharmacy              | Refer to the Department of Law   |
| • S.P.                            | Wholesaler Pharmacy                 | Tabled to allow additional time for review                               |

### Correspondences/Requests

• C.C.V.S.S.I.S.	Notice of Discipline	No action
• L.L.C.P.S.I.	Notice of Discipline	No action
• D.I.P.C.A.	Notice of Discipline	No action
• D.P.S.	Notice of Discipline	No action
• D.P.S.	Notice of Discipline	No action
• S.	Notice of Discipline	No action
• I.P.C.	Notice of Discipline	No action
• I.P.C.	Notice of Discipline	No action
• B.	Notice of Discipline	No action
• T.P.U.I.	Notice of Discipline	No action
• P.S.	Notice of Discipline	No action
• H.P.	Notice of Discipline	No action
• P.S.P.	Notice of Discipline	No action
• C.C.S.M.	Notice of Discipline	No action
• C.C.S.M.	Notice of Discipline	No action
• C.C.S.M.	Notice of Discipline	No action
• C.C.S.M.	Notice of Discipline	No action
• H.B.I.	Notice of Discipline	No action
• P.C.C.	Notice of Discipline	No action
• W.P.N.	Notice of Discipline	No action
• W.P.N.	Notice of Discipline	No action
• P.E.H.	Appearance Request	Approved request
• T.S.Q.	Appearance Request	Approved request
• A.E.B.	Request to lift PIC restriction	Approved request
• M.C.P.	Request to terminate probation	Approved request
• J.C.H.	Request to reinstate pharmacist license	Denied request
• J.A.S.	Appealing denial of request for 5 <sup>th</sup> attempt at NAPLEX	Upheld denial
• A.J.	Request for 5 <sup>th</sup> attempt at MPJE	Approved request
• D.W.W.	Request for 4 <sup>th</sup> attempt at MPJE	Approved request
• E.N.D.	Request for 4 <sup>th</sup> attempt at NAPLEX and MPJE	Denied request regarding NAPLEX/Approved request regarding MPJE
• L.H.J.	Appearance request	Approved request

Mr. Stone seconded and the Board voted unanimously in favor of the motion.

### Miscellaneous

Mr. Lacefield provided an update concerning HHS announcements. He stated that board staff sent all the inconsistencies to the Governor's office. He stated that the Governor's office is currently working with DPH on what action may be needed and expects to have additional information to share in a few weeks.

There being no further business to discuss, the meeting was adjourned at 4:26 p.m.

The next scheduled meeting of the Georgia Board of Pharmacy will be held via conference call on Wednesday, December 16, 2020 at 9:00 a.m., at the Department of Community Health's office located at 2 Peachtree Street, N.W., 6<sup>th</sup> floor, Atlanta, GA 30303.

Minutes recorded by Brandi Howell, Business Support Analyst I  
Minutes edited by Eric Lacefield, Executive Director